Welcome to our dedicated page for American Oncology Network news (Ticker: AONC), a resource for investors and traders seeking the latest updates and insights on American Oncology Network stock.
American Oncology Network Inc (AONC) generates news through practice partnerships, geographic expansion, and clinical research activities. The company's business development announcements reveal its strategy for building a national network of community-based cancer care providers while maintaining physician-led governance.
News coverage for American Oncology Network typically includes partnership announcements with independent oncology and hematology practices joining the network. These affiliation deals expand the company's geographic footprint and add specialized capabilities across different cancer care markets. The network's expansion strategy focuses on preserving local practice identity while integrating operational infrastructure.
Clinical research developments represent another significant news category, as the network presents findings at major oncology conferences and announces participation in multi-site clinical trials. These research activities demonstrate the company's ability to bring investigational therapies to community settings and contribute to cancer treatment evidence.
Regulatory developments, laboratory accreditation milestones, and leadership appointments also generate newsworthy updates. The network's central laboratory services require ongoing certification and compliance oversight, while executive team changes reflect the organization's growth trajectory and strategic priorities.
Track American Oncology Network news to monitor how the physician-led oncology network model evolves in response to healthcare consolidation trends, reimbursement policy changes, and advances in precision medicine that require sophisticated diagnostic and treatment capabilities in community settings.
American Oncology Network (NASDAQ:AONC) and Lone Star Oncology announced that Derrick Nguyen, MD, FACP joined Lone Star Oncology's physician team and is accepting new patients as of Jan. 6, 2026. Dr. Nguyen is a Board-certified medical oncologist with over 15 years of practice, trained at the University of Texas Health Science Center and completed residency at the University of New Mexico Health Sciences Center.
Lone Star Oncology opened in June 2023 and joined AON, expanding local access to infusion therapy, centralized lab and pathology, oral oncolytic delivery and financial counseling through the network partnership.
American Oncology Network (NASDAQ:AONC) announced the appointment of Robert J. McDonald, MD, FACNM, as Radiology Medical Director and in-house reading radiologist, effective Dec. 10, 2025. Dr. McDonald will serve as primary reading radiologist for Florida Oncology & Hematology in Naples and Fort Myers and Central Georgia Cancer Care in Macon, provide PET/CT interpretations, perform advanced radiotheranostic therapies at Naples and Fort Myers, and oversee radiology services at supported practices.
He will lead NRC-required clinical preceptorships, refine RLT protocols, and support rollout of newly FDA-approved radiotheranostic therapies as AONC expands RLT capabilities into 2026. Dr. McDonald brings >30 years of diagnostic imaging and radioligand therapy experience.
Hawai’i Cancer Care (AONC partner) opened a new clinic in Kahului, Hawai’i on Dec. 2, 2025 at 17 La’a Street, Unit B, expanding to three statewide locations.
Board-certified oncologists Dr. Melvin P. Palalay and Dr. David J. Tamura and nurse practitioner Judy Ko, RN, MSN, APRN are accepting patients. The clinic offers private exam rooms and an infusion room and will be open on Tuesdays and Wednesdays. New and existing patients can call (808) 727-8341 to schedule appointments.
The practice emphasizes patient-centered, research-based cancer and blood-disorder care, aiming to reduce travel for Maui patients and provide diagnosis, treatment, survivorship, and support locally.
American Oncology Network (NASDAQ:AONC) announced that 15 research abstracts by AON physicians and leaders were accepted for presentation at the ASCO Quality Care Symposium 2025, held Oct. 10-11 in Chicago. Topics span cost of care, the Enhancing Oncology Model (EOM), inflation impacts on reimbursement, biosimilar and Medicare reimbursement policy, episode groupers, clinical adjusters, geography and social deprivation, end-of-life therapy patterns, and outcomes for pembrolizumab weight-based dosing.
The abstracts credit AON leaders and collaborations with Thyme Care and highlight AON’s focus on value-based care, real-world data, and community oncology practice improvements.
American Oncology Network (AONC) and partner practice The Center for Cancer and Blood Disorders announced that board-certified medical oncologist Dr. Chitra Rajagopal has joined the CCBD physician team in Germantown and Bethesda, Maryland.
Dr. Raj trained at Stanley Medical College and completed internal medicine residency at SUNY Downstate and hematology/oncology and bone marrow transplant fellowships at Georgetown Lombardi Cancer Center. She has practiced community-based oncology since 1997 and holds professional society memberships.
Dr. Raj is seeing patients three days weekly in Germantown (primary site) and will expand to four days weekly beginning in January.
American Oncology Network (NASDAQ:AONC) announced that Genesis Cancer and Blood Institute, an AON partner practice, has welcomed Dr. Beau Hilton to its physician care team. Dr. Hilton, who earned his medical degree from Cleveland Clinic Lerner College of Medicine and completed his training at Vanderbilt University Medical Center, joins a team of 10 other medical oncologists.
Genesis Cancer and Blood Institute operates across 11 locations in Arkansas, offering comprehensive cancer services including diagnosis, treatment, clinical trials, and patient support. Dr. Hilton began seeing patients at Genesis Hot Springs clinics on September 1, 2025.
American Oncology Network (AONC) reported exceptional growth for the 12 months ended June 30, 2025, with annual revenue exceeding $2 billion, representing over 40% growth year-over-year. The network has expanded to include more than 300 oncology and hematology providers across 20 states.
Key achievements include the launch of bispecific T-cell engager therapies in 40+ clinics, expansion of radioligand therapies, and implementation of AI-enabled clinical trial matching. The company demonstrated strong value-based care performance, achieving $6 million in CMS cost savings and $2.7 million in commercial savings. Partner practices average a 30% increase in sustainable income after joining AON.
American Oncology Network (NASDAQ:AONC) and The Center for Cancer and Blood Disorders (CCBD) have announced the addition of two board-certified medical oncologists to their physician team. Dr. Garrett Diltz and Dr. Shreya Desai will serve patients in Bethesda and Germantown, Maryland.
Dr. Diltz, a graduate of The Ohio State University College of Medicine, completed his fellowship at MedStar Georgetown University Hospital. Dr. Desai, fluent in Gujarati and Hindi, completed her fellowship at the Medical College of Georgia. Both physicians will join CCBD's comprehensive cancer care services, which include diagnostics, treatments, clinical trials, and survivorship programs.
American Oncology Network (NASDAQ:AONC) announced that Genesis Cancer and Blood Institute, its partner practice, has welcomed Dr. Tyler Fugere to its physician care team. Dr. Fugere, a Board-certified medical oncologist and hematologist, joins a team of experienced physicians at Genesis, which operates 11 locations across Arkansas.
Dr. Fugere earned her medical degree, completed her internal medicine residency, and hematology-oncology fellowship at the University of Arkansas for Medical Sciences. She began seeing patients at Genesis's Benton and Little Rock clinics on August 1, 2025. Genesis Cancer and Blood Institute offers comprehensive services including cancer diagnosis, treatment, clinical trials, survivorship, and patient support services.
American Oncology Network (NASDAQ:AONC) has expanded its presence in Arkansas by welcoming Conway Hematology Oncology (CHO) to its network of community-based oncology practices. Founded in 1998 by Dr. Sue Tsuda, CHO has been providing hematology and oncology care in Conway for over 25 years.
The partnership will enable CHO to expand patient services, increase clinical trial offerings, and explore new market opportunities while maintaining their commitment to high-quality care. The practice features comprehensive oncology services, including advanced diagnostic and treatment technologies, an onsite laboratory, and private infusion suites.
The medical team includes Dr. Tsuda, a Board-certified medical oncologist and hematologist, along with two experienced Board-certified nurse practitioners, Christine Lightfoot and Courtney Nash.
FAQ
What is the current stock price of American Oncology Network (AONC)?
What is the market cap of American Oncology Network (AONC)?
